For nonsubscribers, we’ve made our annual feature on the health of the private biotech space freely available. Many of the data are supplied by Dow Jones VentureSource, tailored to our requests and definitions of biotech, and highlight what some already know: venture capital funding for early stage innnovative companies continues to dwindle. The article also investigates start-up activity from universities, exits and more. Go here for the PDF, and here for HTML version.
This follows up on last year’s article, which is also free and can be found here.